Cargando…
Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing
Persistent latent reservoir of replication-competent proviruses in memory CD4 T cells is a major obstacle to curing HIV infection. Pharmacological activation of HIV expression in latently infected cells is being explored as one of the strategies to deplete the latent HIV reservoir. In this study, we...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3983056/ https://www.ncbi.nlm.nih.gov/pubmed/24722454 http://dx.doi.org/10.1371/journal.ppat.1004071 |
_version_ | 1782311250965823488 |
---|---|
author | Wei, Datsen George Chiang, Vicki Fyne, Elizabeth Balakrishnan, Mini Barnes, Tiffany Graupe, Michael Hesselgesser, Joseph Irrinki, Alivelu Murry, Jeffrey P. Stepan, George Stray, Kirsten M. Tsai, Angela Yu, Helen Spindler, Jonathan Kearney, Mary Spina, Celsa A. McMahon, Deborah Lalezari, Jacob Sloan, Derek Mellors, John Geleziunas, Romas Cihlar, Tomas |
author_facet | Wei, Datsen George Chiang, Vicki Fyne, Elizabeth Balakrishnan, Mini Barnes, Tiffany Graupe, Michael Hesselgesser, Joseph Irrinki, Alivelu Murry, Jeffrey P. Stepan, George Stray, Kirsten M. Tsai, Angela Yu, Helen Spindler, Jonathan Kearney, Mary Spina, Celsa A. McMahon, Deborah Lalezari, Jacob Sloan, Derek Mellors, John Geleziunas, Romas Cihlar, Tomas |
author_sort | Wei, Datsen George |
collection | PubMed |
description | Persistent latent reservoir of replication-competent proviruses in memory CD4 T cells is a major obstacle to curing HIV infection. Pharmacological activation of HIV expression in latently infected cells is being explored as one of the strategies to deplete the latent HIV reservoir. In this study, we characterized the ability of romidepsin (RMD), a histone deacetylase inhibitor approved for the treatment of T-cell lymphomas, to activate the expression of latent HIV. In an in vitro T-cell model of HIV latency, RMD was the most potent inducer of HIV (EC(50) = 4.5 nM) compared with vorinostat (VOR; EC(50) = 3,950 nM) and other histone deacetylase (HDAC) inhibitors in clinical development including panobinostat (PNB; EC(50) = 10 nM). The HIV induction potencies of RMD, VOR, and PNB paralleled their inhibitory activities against multiple human HDAC isoenzymes. In both resting and memory CD4 T cells isolated from HIV-infected patients on suppressive combination antiretroviral therapy (cART), a 4-hour exposure to 40 nM RMD induced a mean 6-fold increase in intracellular HIV RNA levels, whereas a 24-hour treatment with 1 µM VOR resulted in 2- to 3-fold increases. RMD-induced intracellular HIV RNA expression persisted for 48 hours and correlated with sustained inhibition of cell-associated HDAC activity. By comparison, the induction of HIV RNA by VOR and PNB was transient and diminished after 24 hours. RMD also increased levels of extracellular HIV RNA and virions from both memory and resting CD4 T-cell cultures. The activation of HIV expression was observed at RMD concentrations below the drug plasma levels achieved by doses used in patients treated for T-cell lymphomas. In conclusion, RMD induces HIV expression ex vivo at concentrations that can be achieved clinically, indicating that the drug may reactivate latent HIV in patients on suppressive cART. |
format | Online Article Text |
id | pubmed-3983056 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-39830562014-04-15 Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing Wei, Datsen George Chiang, Vicki Fyne, Elizabeth Balakrishnan, Mini Barnes, Tiffany Graupe, Michael Hesselgesser, Joseph Irrinki, Alivelu Murry, Jeffrey P. Stepan, George Stray, Kirsten M. Tsai, Angela Yu, Helen Spindler, Jonathan Kearney, Mary Spina, Celsa A. McMahon, Deborah Lalezari, Jacob Sloan, Derek Mellors, John Geleziunas, Romas Cihlar, Tomas PLoS Pathog Research Article Persistent latent reservoir of replication-competent proviruses in memory CD4 T cells is a major obstacle to curing HIV infection. Pharmacological activation of HIV expression in latently infected cells is being explored as one of the strategies to deplete the latent HIV reservoir. In this study, we characterized the ability of romidepsin (RMD), a histone deacetylase inhibitor approved for the treatment of T-cell lymphomas, to activate the expression of latent HIV. In an in vitro T-cell model of HIV latency, RMD was the most potent inducer of HIV (EC(50) = 4.5 nM) compared with vorinostat (VOR; EC(50) = 3,950 nM) and other histone deacetylase (HDAC) inhibitors in clinical development including panobinostat (PNB; EC(50) = 10 nM). The HIV induction potencies of RMD, VOR, and PNB paralleled their inhibitory activities against multiple human HDAC isoenzymes. In both resting and memory CD4 T cells isolated from HIV-infected patients on suppressive combination antiretroviral therapy (cART), a 4-hour exposure to 40 nM RMD induced a mean 6-fold increase in intracellular HIV RNA levels, whereas a 24-hour treatment with 1 µM VOR resulted in 2- to 3-fold increases. RMD-induced intracellular HIV RNA expression persisted for 48 hours and correlated with sustained inhibition of cell-associated HDAC activity. By comparison, the induction of HIV RNA by VOR and PNB was transient and diminished after 24 hours. RMD also increased levels of extracellular HIV RNA and virions from both memory and resting CD4 T-cell cultures. The activation of HIV expression was observed at RMD concentrations below the drug plasma levels achieved by doses used in patients treated for T-cell lymphomas. In conclusion, RMD induces HIV expression ex vivo at concentrations that can be achieved clinically, indicating that the drug may reactivate latent HIV in patients on suppressive cART. Public Library of Science 2014-04-10 /pmc/articles/PMC3983056/ /pubmed/24722454 http://dx.doi.org/10.1371/journal.ppat.1004071 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. |
spellingShingle | Research Article Wei, Datsen George Chiang, Vicki Fyne, Elizabeth Balakrishnan, Mini Barnes, Tiffany Graupe, Michael Hesselgesser, Joseph Irrinki, Alivelu Murry, Jeffrey P. Stepan, George Stray, Kirsten M. Tsai, Angela Yu, Helen Spindler, Jonathan Kearney, Mary Spina, Celsa A. McMahon, Deborah Lalezari, Jacob Sloan, Derek Mellors, John Geleziunas, Romas Cihlar, Tomas Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing |
title | Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing |
title_full | Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing |
title_fullStr | Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing |
title_full_unstemmed | Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing |
title_short | Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing |
title_sort | histone deacetylase inhibitor romidepsin induces hiv expression in cd4 t cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3983056/ https://www.ncbi.nlm.nih.gov/pubmed/24722454 http://dx.doi.org/10.1371/journal.ppat.1004071 |
work_keys_str_mv | AT weidatsengeorge histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing AT chiangvicki histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing AT fyneelizabeth histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing AT balakrishnanmini histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing AT barnestiffany histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing AT graupemichael histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing AT hesselgesserjoseph histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing AT irrinkialivelu histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing AT murryjeffreyp histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing AT stepangeorge histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing AT straykirstenm histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing AT tsaiangela histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing AT yuhelen histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing AT spindlerjonathan histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing AT kearneymary histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing AT spinacelsaa histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing AT mcmahondeborah histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing AT lalezarijacob histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing AT sloanderek histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing AT mellorsjohn histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing AT geleziunasromas histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing AT cihlartomas histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing |